Regenerative medicine Gilbert: blood-based shots for joint soreness

Wear or a strained tendon often causes the ache

Arthritis often leaves a joint stiff after you've been sitting. A sore shoulder may hurt when you reach overhead. A worn hip may ache during a long walk. A knee may feel stiff during the first standing steps.

Notice which motion starts the soreness and what calms it. Swelling, catching, weakness, and lost motion are also worth noting. Your doctor can use those details with the exam and X-ray. Soreness alone can't tell you whether wear or an injury is responsible.

The motion that hurts is useful information.

Heat and marked swelling together need prompt medical care. Fever raises the urgency. Seek help if a leg won't hold your weight after a fall. Night soreness that continues or fast loss of motion also merits a visit.

The exam comes before any treatment choice

You'll describe how long the ache has lasted and what affects it. The doctor checks how it moves and how strong it feels. Swollen or tender areas matter too. Older X-rays and a current pill list can keep the visit focused.

After the exam, QC Kinetix may offer regenerative treatments, including a shot prepared from blood, for soreness that may come with arthritis. For a knee or hip, the doctor may compare exercise, medicine, the blood-based shot, and surgery. The exam helps show which choices make sense for your joint.

One treatment can't suit every cause of soreness.

Ask how much pain relief you might get and how long it may last. The full price, time needed afterward, and next choice also matter. You'll be better prepared when those answers are clear.

Sources

1. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, 2020.

2. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

3. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit.

   Awad G, et al. — Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.. Clinical rheumatology, 2026. DOI: 10.1007/s10067-026-08042-w.

4. The AAOS third-edition clinical practice guideline for non-arthroplasty management of knee osteoarthritis is the orthopedic profession's own GRADE-style appraisal of the same options a regenerative clinic sells; it is the benchmark against which any 'regenerative' claim on this topic should be read, and it rates the strongest support for exercise, weight loss and self-management rather than for injectables.

   Brophy RH, et al. — AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition.. The Journal of the American Academy of Orthopaedic Surgeons, 2022. DOI: 10.5435/JAAOS-D-21-01233.